The rate-limiting step of protein synthesis in vivo and in vitro and the distribution of growing peptides between the puromycin-labile and puromycin-non-labile sites on polyribosomes.
1. At 3 min after an intravenous injection of radioactive amino acids into the rat, the bulk of radioactivity associated with liver polyribosomes can be interpreted as growing peptides. 2. In an attempt to identify the rate-limiting step of protein synthesis in vivo and in vitro, use was made of the action of puromycin at 0 degrees C, in releasing growing peptides only from the donor site, to study the distribution of growing peptides between the donor and acceptor sites. 3. Evidence is presented that all growing peptides in a population of liver polyribosomes labelled in vivo are similarly distributed between the donor and acceptor sites, and that the proportion released by puromycin is not an artifact of methodology. 4. The proportion released by puromycin is about 50% for both liver and muscle polyribosomes labelled in vivo, suggesting that neither the availability nor binding of aminoacyl-tRNA nor peptide bond synthesis nor translocation can limit the rate of protein synthesis in vivo. Attempts to alter this by starvation, hypophysectomy, growth hormone, alloxan, insulin and partial hepatectomy were unsuccessful. 5. Growing peptides on liver polyribosomes labelled in a cell-free system in vitro or by incubating hemidiaphragms in vitro were largely in the donor site, suggesting that either the availability or binding of aminoacyl-tRNA, or peptide bond synthesis, must be rate limiting in vitro and that the rate-limiting step differs from that in vivo. 6. Neither in vivo nor in the hemidiaphragm system in vitro was a correlation found between the proportion of growing peptides in the donor site and changes in the rate of incorporation of radioactivity into protein. This could indicate that the intracellular concentration of amino acids or aminoacyl-tRNA limits the rate of protein synthesis and that the increased incorporation results from a rise to a higher but still suboptimum concentration.
D000496:Alloxan / Q000494:pharmacology; D000596:Amino Acids / Q000378:metabolism; D000818:Animals; D001665:Binding Sites; D002247:Carbon Isotopes; D002499:Centrifugation, Density Gradient; D002845:Chromatography; D003964:Diaphragm / Q000378:metabolism; D013006:Growth Hormone / Q000494:pharmacology; D006498:Hepatectomy; D007016:Hypophysectomy; D066298:In Vitro Techniques; D007328:Insulin / Q000494:pharmacology; D007700:Kinetics; D008099:Liver / Q000378:metabolism; D008297:Male; D009132:Muscles / Q000378:metabolism; D010455:Peptides / Q000378:metabolism*; D014176:Protein Biosynthesis; D011691:Puromycin / Q000494:pharmacology*; D051381:Rats; D012270:Ribosomes / Q000187:drug effects* / Q000378:metabolism; D013217:Starvation / Q000378:metabolism
D000596:Amino Acids; D002247:Carbon Isotopes; D007328:Insulin; D010455:Peptides; D011691:Puromycin; D000496:Alloxan; D013006:Growth Hormone